Lipella PharmaceuticalsLIPO +8.43% PB Ratio is 0.28 as of Jun. 26, 2026, which is 85% below its 10-year median of 1.91. The stock has 1 warning sign investors should review. Among 1,232 Biotechnology companies, Lipella Pharmaceuticals ranks better than 97.24% on this metric.
The historical rank and industry rank for Lipella Pharmaceuticals's PB Ratio or its related term are showing as below:
LIPO'
s PB Ratio Range Over the Past 10 Years
Min: 0.06 Med: 1.91 Max: 5.46
Current: 0.28
During the past 5 years, Lipella Pharmaceuticals's highest PB Ratio was 5.46. The lowest was 0.06. And the median was 1.91.
LIPO's PB Ratio is ranked better than 97.24% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs LIPO: 0.28
During the past 12 months, Lipella Pharmaceuticals's average Book Value Per Share Growth Rate was -75.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -7.20% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Lipella Pharmaceuticals was 86.00% per year. The lowest was -7.20% per year. And the median was 39.40% per year.
Back to Basics: PB Ratio
Lipella Pharmaceuticals (OTCPK:LIPO) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lipella Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lipella Pharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lipella Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Lipella Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Lipella Pharmaceuticals (LIPO) has a PB Ratio of 0.28 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Lipella Pharmaceuticals and its competitors. This is 85% below median its historical median of 1.91. Over the past decade, Lipella Pharmaceuticals' PB Ratio has ranged from 0.06 to 5.46. According to the industry distribution chart, Lipella Pharmaceuticals ranks #34 out of 1232 companies in the Biotechnology industry, placing it in the top 2.8%.
Is Lipella Pharmaceuticals' PB Ratio too high?
Lipella Pharmaceuticals' current PB Ratio of 0.28 is 85% below median its 10-year median of 1.91. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 5.46. The Biotechnology industry median PB Ratio is 2.80. Lipella Pharmaceuticals' value of 0.28 is 90% below this industry median. Based on the distribution chart, Lipella Pharmaceuticals ranks #34 out of 1232 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Lipella Pharmaceuticals' PB Ratio compare to WINT and RMTG?
According to the Biotechnology industry distribution chart, Lipella Pharmaceuticals ranks #34 out of 1232 companies for PB Ratio. This places Lipella Pharmaceuticals in the top 3% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.80. Lipella Pharmaceuticals' value of 0.28 is 90% below this benchmark. Historically, Lipella Pharmaceuticals' own PB Ratio has ranged from 0.06 to 5.46 over the past decade. While the company's 10-year median is 1.91 vs. the industry median of 2.80, Lipella Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lipella Pharmaceuticals's current PB Ratio of 0.28 is 90% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Lipella Pharmaceuticals and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lipella Pharmaceuticals's current PB Ratio is 0.28, which is 85% below median its own 10-year median of 1.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipella Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Lipella Pharmaceuticals (LIPO) is currently considered Possible Value Trap. The stock's GF Value™ is $8.67, compared to a current price of $0.09 — trading 99% below its estimated fair value. The current PB Ratio is 0.28, which is 85% below median its 10-year median of 1.91 and 90% below the Biotechnology industry median of 2.80. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Lipella Pharmaceuticals (LIPO), the current PB Ratio is 0.28 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410, which can be helpful in the treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LIPO has been successfully added to your 